Daewoong, Peptron Agree on Joint Development of Acromegaly Treatment
Published: 2004-12-31 06:55:00
Updated: 2004-12-31 06:55:00
Daewoong Pharmaceutical announced on December 30th that it has made a joint development agreement with Peptron Inc., a local biotech venture company, to collaborate on developing the treatment for acromegaly with octreotide as an active ingredient.
Octreotide is a synthetic protein which helps...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
